Home LiteratureArticle Details
PMID: 10756031 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.

Journal of virology ·Vol. 74 ·No. 9 ·2000-05-00 ·Pages 4183-91

Park EJ, Gorny MK, Zolla-Pazner S, Quinnan GV

Abstract

We have described previously genetic characterization of neutralization-resistant, high-infectivity, and neutralization-sensitive, low-infectivity mutants of human immunodeficiency virus type 1 (HIV-1) MN envelope. The distinct phenotypes of these clones are attributable to six mutations affecting functional interactions between the gp120 C4-V5 regions and the gp41 leucine zipper. In the present study we examined mechanisms responsible for the phenotypic differences between these envelopes using neutralization and immunofluorescence assays (IFA). Most monoclonal antibodies (MAbs) tested against gp120 epitopes (V3, CD4 binding site, and CD4-induced) were 20 to 100 times more efficient at neutralizing pseudovirus expressing sensitive rather than resistant envelope. By IFA cells expressing neutralization sensitive envelope bound MAbs to gp120 epitopes more, but gp41 epitopes less, than neutralization-resistant envelope. This binding difference appeared to reflect conformational change, since it did not correlate with the level of protein expression or gp120-gp41 dissociation. This conformational change was mostly attributable to one mutation, L544P, which contributes to neutralization resistance but not to infectivity enhancement. The V420I mutation, which contributes a major effect to both high infectivity and neutralization resistance, had no apparent effect on conformation. Notably, a conformation-dependent V3 neutralization epitope remained sensitive to neutralization and accessible to binding by MAbs on neutralization-resistant HIV-1 envelope. Sensitivity to sCD4 did not distinguish the clones, suggesting that the phenotypes may be related to post-CD4-binding effects. The results demonstrate that neutralization resistance can be determined by distinguishable effects of mutations, which cause changes in envelope conformation and/or function(s) related to infectivity. A conformation-dependent V3 epitope may be an important target for neutralization of resistant strains of HIV-1.

MeSH Terms
Antibodies, Monoclonal/immunology CD4 Antigens/immunology Epitopes, B-Lymphocyte/chemistry,genetics,immunology Flow Cytometry/methods HIV Antibodies/immunology HIV Envelope Protein gp120/genetics,immunology HIV Envelope Protein gp41/chemistry,genetics,immunology HIV-1/genetics,immunology,physiology Humans Immunophenotyping Neutralization Tests Peptide Fragments/genetics,immunology Protein Conformation
Chemicals
Antibodies, Monoclonal CD4 Antigens Epitopes, B-Lymphocyte HIV Antibodies HIV Envelope Protein gp120 HIV Envelope Protein gp41 HIV envelope protein gp120 (305-321) Peptide Fragments
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Park E J
Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA.
Gorny M K
Zolla-Pazner S
Quinnan G V
References (34)
34 references, click to expand
  1. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.
    AIDS. 1996 Jun;10(6):587-93 PMID: 8780812
  2. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.
    J Virol. 1999 Jul;73(7):5707-13 PMID: 10364321
  3. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
    Int Immunol. 1997 Sep;9(9):1281-90 PMID: 9310831
  4. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.
    J Immunol. 1997 Nov 15;159(10):5114-22 PMID: 9366441
  5. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
    AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1549-59 PMID: 9430247
  6. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  7. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  8. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
    J Virol. 1998 Sep;72(9):7099-107 PMID: 9696803
  9. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.
    Cell. 1988 Jul 1;54(1):57-63 PMID: 2838179
  10. Human immunodeficiency viruses: neutralization and receptors.
    J Acquir Immune Defic Syndr. 1988;1(6):536-41 PMID: 2465401
  11. Generation of human monoclonal antibodies to human immunodeficiency virus.
    Proc Natl Acad Sci U S A. 1989 Mar;86(5):1624-8 PMID: 2922401
  12. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.
    J Virol. 1990 Jul;64(7):3240-8 PMID: 2352323
  13. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3238-42 PMID: 2014246
  14. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.
    J Immunol. 1991 Jun 15;146(12):4325-32 PMID: 1710248
  15. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.
    J Virol. 1991 Sep;65(9):4832-8 PMID: 1714520
  16. Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators.
    AIDS. 1991 Sep;5(9):1061-70 PMID: 1718320
  17. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.
    Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134-7 PMID: 1719545
  18. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.
    Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10164-8 PMID: 1279672
  19. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.
    J Acquir Immune Defic Syndr. 1993 Jan;6(1):7-14 PMID: 8417177
  20. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
    J Immunol. 1993 Jan 15;150(2):635-43 PMID: 7678279
  21. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  22. Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.
    J Virol. 1993 Dec;67(12):7493-500 PMID: 7693973
  23. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.
    J Virol. 1994 Feb;68(2):674-80 PMID: 7507184
  24. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):4821-8 PMID: 7518527
  25. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.
    AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69 PMID: 7520721
  26. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.
    J Virol. 1994 Nov;68(11):6994-7000 PMID: 7933081
  27. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
    Mol Immunol. 1994 Oct;31(15):1149-60 PMID: 7935503
  28. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.
    J Virol. 1995 Jan;69(1):122-30 PMID: 7527082
  29. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  30. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  31. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection.
    J Virol. 1996 Aug;70(8):5306-11 PMID: 8764041
  32. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
    J Virol. 1998 Oct;72(10):7840-5 PMID: 9733820
  33. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.
    J Virol. 1999 Jun;73(6):5225-30 PMID: 10233993
  34. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
    J Virol. 1996 Dec;70(12):8431-7 PMID: 8970964
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2000-05-00
Pages
4183-91
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC111933
Subset
IM
Grants
NIAID NIH HHS · R01 AI036085 · United States
NIAID NIH HHS · AI32424 · United States
NHLBI NIH HHS · R01 HL059725 · United States
NHLBI NIH HHS · HL AI/HL 36085 · United States
NIAID NIH HHS · R01-AI37438 · United States
NIAID NIH HHS · R01 AI037438 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com